These medications can be remarkably effective, but we see them as part of a much bigger picture. For many patients, weight gain is linked to a combination of factors such as stress, busy lifestyles, poor sleep, hormonal changes, emotional eating, or years of struggling with appetite and cravings.
Medications such as Wegovy (semaglutide) and Mounjaro (tirzepatide) have transformed the medical treatment of obesity and weight management. They are primarily prescribed to help patients achieve meaningful and sustained weight loss, working by regulating appetite, improving satiety and helping to reduce overall calorie intake.
In clinical trials, many patients experience substantial weight reduction when these medications are combined with supportive lifestyle changes. While their main role remains weight loss, a rapidly growing body of research shows that these medications can also provide wider health benefits, including improvements in cardiovascular risk factors, blood sugar control, blood pressure and metabolic health.
As a result, they are increasingly recognised not only for helping patients lose weight, but also for supporting broader long-term health and disease prevention. At The Wright Practice, Dr Dan Wright and Dr Susan Jain take a personalised, carefully monitored approach from the start, working with a team that includes nutritionists and psychotherapists.
Both Wegovy (semaglutide) and Mounjaro (tirzepatide) work by mimicking natural gut hormones called incretins, which regulate appetite and blood sugar. They slow the passage of food through the digestive system, signal the brain to reduce hunger, and lower the constant background “food noise” that many people with persistent weight gain describe.
Wegovy is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of drug that mimics a natural appetite hormone. Mounjaro works on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), making it a dual-action medication that may produce stronger appetite suppression in some patients. Both are given as a once-weekly subcutaneous injection, which Dr Dan will show you how to administer yourself.
Beyond weight loss, a growing body of research shows these medications also support cardiovascular health, improve blood pressure and blood sugar control, and reduce metabolic risk. You can read more in our blog post on how Wegovy and Mounjaro protect your heart.
The primary goal is meaningful, sustained weight loss. Beyond that, patients often report improvements in energy, sleep quality, mobility, blood pressure, and blood sugar control. For patients with type 2 diabetes or pre-diabetes, improved blood sugar regulation is an additional benefit. For those with cardiovascular risk factors, the evidence for protective effects is now substantial.
Mounjaro’s dual mechanism generally produces stronger appetite suppression and greater average weight loss in clinical trials. Both medications are effective, and the right choice depends on your medical history, current medications, and individual response. Dr Dan and Dr Susan will advise based on your specific circumstances.
| Wegovy (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|
Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist |
Administration | Once-weekly injection | Once-weekly injection |
Starting dose | 0.25 mg | 2.5 mg |
Typical weight loss | 10 to 15% of body weight | 15 to 20% of body weight |
Common side effects | Nausea, constipation, diarrhoea | Nausea, constipation, diarrhoea |
Cost from | £210 per month | £250 per month |
These medications are appropriate for adults with a BMI of 30 or above, or a BMI of 27 or above alongside a weight-related health condition such as type 2 diabetes, hypertension, or high cholesterol.
They may not be suitable if you have a personal or family history of medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2), are pregnant or breastfeeding, have severe gastrointestinal conditions, or have certain pancreatic conditions. Dr Dan will review your full medical history before prescribing.
At The Wright Practice, weight management is not a prescription and a goodbye. It is a monitored programme with regular check-ins, nutritional support, and honest conversations about progress, side effects, and adjustments.
The programme includes: an initial consultation covering your medical history, weight history, lifestyle, and goals; instruction on injection technique; a personalised nutrition plan; exercise and movement guidance; quarterly reviews with Dr Dan or Dr Susan; ongoing support by phone and email; and monthly medication delivery.
A weight loss membership is available at £95 per month (excluding medication and initial consultation), with a minimum commitment of three months.
The most common side effects are nausea, constipation, diarrhoea, and abdominal discomfort. These are most pronounced during the early dose-escalation phase and typically improve as the body adjusts. Eating smaller meals and avoiding very fatty foods can help.
Less common but more serious side effects include pancreatitis and gallbladder problems. Dr Dan will discuss these with you before starting treatment and will monitor for any concerns during the programme. Semaglutide and tirzepatide have been used in clinical trials and clinical practice for over a decade and both are well-studied, licensed medications.
The initial weight loss consultation is £195. Wegovy injections start from £210 per monthly pen and Mounjaro from £250 per monthly pen. A weight loss membership at £95 per month covers ongoing medical support, nutritional guidance, and regular check-ins, with medication charged separately. Full pricing is on the pricing page.
Dr Dan Wright and Dr Susan Jain take a whole-person view of weight management. Weight gain is rarely the result of a single cause: genetics, hormones, stress, sleep, emotional patterns, and a history of struggling with appetite all play a role. The programme is built around that understanding.
Wow! Dr. Dan was extremely knowledgeable and attentive to my health and well being. I’m so glad to have found him!
I have been going to Dr Wright for a number of years now. He is highly knowledgeable, compassionate, open minded and efficient, I couldn’t recommend him highly enough
I have been a patient of Doctor Dan for some time and continue to consult with him despite having left the UK. Dan has the enthusiasm and energy of a young man, whilst taking the holistic “physician” approach of an old school family doctor, equipped with the most modern insights and technology.
Dr Jain was great. Expert knowledge with practical advice
Both medications are licensed in the UK and have been studied extensively. Semaglutide has been in clinical use for over a decade, originally as a diabetes treatment. Mounjaro (tirzepatide) received UK approval for weight management in 2023. Both have well-established safety profiles. Dr Dan will review your medical history and discuss any specific risks before prescribing.
Both are given as a once-weekly subcutaneous (under the skin) injection, typically into the abdomen, thigh, or upper arm. Dr Dan will show you how to do this at your initial consultation.
These medications work best alongside healthy eating habits. You do not need to follow a rigid diet, but reducing portion sizes and limiting very fatty foods will help manage side effects and support results. Our nutritionist will provide personalised guidance.
Some weight regain is common when GLP-1 medications are stopped, as appetite tends to return. Patients who have used the programme to build healthier habits typically maintain more of their results. Dr Dan will discuss a plan for transitioning off medication at the right time.
Dr Dan or Dr Susan will review your progress quarterly as standard. Between appointments, support is available by phone and email.
Yes. Both medications were originally developed for type 2 diabetes management. Dr Dan will review your current diabetes medications to avoid any interactions or risk of hypoglycaemia.
Dr Dan or Dr Susan will take a full medical history, discuss your weight history and goals, measure your BMI, review any blood tests needed, explain how the medication works, and if appropriate, provide instruction on injection technique and issue your first prescription.
Wegovy contains semaglutide and works on GLP-1 receptors. Mounjaro contains tirzepatide and works on both GLP-1 and GIP receptors. Mounjaro’s dual mechanism generally produces stronger appetite suppression and greater average weight loss. The right choice depends on your individual circumstances and medical history.
A 20-minute video review for patients already on a medical weight-management programme with us, including Wegovy and Mounjaro. We check progress, side effects, dose adjustments, and any prescription changes. New patients should book a New Patient Weight Loss Consultation first so we can assess suitability.
Rated ★ ★ ★ ★ ★ from 192 Reviews
